Spica Therapeutics

Spica Therapeutics leverages proprietary functional macrophage fingerprinting technology to identify and selectively target disease-relevant macrophage subsets. Founded on research from the University of Aarhus, Southern Denmark University, and INSERM, the company is advancing two lead programs in oncology and fibroinflammatory diseases.